Comparative Pharmacology
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHALOTHIN SODIUM W SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
1-2 g IV every 4-6 hours; maximum 12 g/day.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 8-12 hours in anuria)
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal excretion (60-70% unchanged); biliary excretion (20-30%); fecal elimination (<1%)
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte